英夫利西单抗治疗重度银屑病17例临床观察
被引量:5
摘要
研究发现,肿瘤坏死因子a(TNF-a)在银屑病的发病中起重要作用。近年来,生物制剂在中、重度银屑病尤其既往治疗中疗效不佳的银屑病患者中应用日益广泛。英夫利西单抗(IFX)是一种人鼠嵌合性抗TNF—a单克隆抗体,美国FDA在2006年批准该药用于治疗银屑病。现将我科自2013年12月以来应用IFX治疗的17例银屑病患者情况报道如下。
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2016年第4期294-295,共2页
Chinese Journal of Dermatology
参考文献10
-
1Gottlieb AB, Chamian F, Masud S, et down-regulates muhiple proinflammatow pathways in psoriasis plaques [ J. ] Immunol, 2005, 175 (4): 2721-2729. DOI: l 0.4049/ jimmunol. 175.4.2721.
-
2Kimber 1, Cumberbatch M, Dearman RJ, et al. Cytokines and chenmkines in the initiation anti regulation of epidermal Langerhans cell mobilization [J ]. Br J Demlatol. 2000, 142 ( 3 ): 401-412. DOI: 10.1046/j.1365-2133.2000.03349.x.
-
3Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis [J ]. Br J Dermatol, 2010, 162 (6): 1349-1358. DOI: 10.1111/j.1365- 2133.2010.09707.x.
-
4Ahmad K, Rogers S. Three years' experience with infliximab in recalcitrant psoriasis[J]. Clin Exp Dermatol, 2006, 31 ( 5 ): 630- 633. DOI: 10.111 l/j.1365-2230.2006.02170.x.
-
5Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referr',d centre [J ]. Br J Dennatol, 2009, 160 (1): 162-169. DOI: 10.1111/j.1365- 2133.2008.08865.x.
-
6余晓玲,晋红中.英夫利西单抗治疗关节病性银屑病进展[J].中华皮肤科杂志,2014,47(3):223-225. 被引量:3
-
7Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis[J]. J Am Aead Dermatol, 2007, 56( 1 ): 31. DOI: 10.1016/ j.jaad.2006.07.017.
-
8张堂德,李琳琳,罗妙璇.英夫利西单抗治疗寻常性银屑病七例[J].中华皮肤科杂志,2015,48(6):438-439. 被引量:3
-
9Fahroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients [J]. J Eur Acad Demlatol Venereol, 2011, 25 (5): 549-553. DOI: 10.1111/j.1468- 3083.2010.03826.x.
-
10G6mez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection [J]. Arthritis Rheum, 2007, 57 (5): 756-761. DOI: 10.1002/art.22768.
二级参考文献19
-
1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3059
-
2Vilma VS,de Carvalho JF,de Moraes JC. Autoantibodies in patients with psoriatic arthritis on anti-TNFa therapy[J].Revista Brasileira de Reumatologia,2010,(03):225-234.
-
3Antoni CE,Kavanaugh A,Kirkham B. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis[J].Arthritis and Rheumatism,2005,(04):1227-1236.
-
4Antoni CE,Kavanaugh A,Van der Heijde D. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis:findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)[J].Journal of Rheumatology,2008,(05):869-876.
-
5Smolen JS,Emery P. Infliximab:12 years of experience[J].Arthritis Research and Therapy,2011,(Suppl 1):1-18.
-
6Voulgari PV,Venetsanopoulou AI,Exarchou SA. Sustained clinical response and high infliximab survival in psoriatic arthritis patients:a 3-year long-term study[J].Seminars in Arthritis and Rheumatism,2008,(05):293-298.
-
7Di Renzo L,Saraceno R,Schipani C. Why 3 mg/kg instead of 5 mg/kg of infliximab should work in psoriatic arthritis[J].Journal of Dermatology,2009,(12):666-668.
-
8Alstergren P,Larsson PT,Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis[J].Scandinavian Journal of Rheumatology,2008,(02):155-157.
-
9Conti F,Ceccarelli F,Priori R. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids.Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha[J].Annals of the Rheumatic Diseases,2008,(12):1787-1790.
-
10Antoni C,Krueger GG,de Vlam K. Infliximab improves signs and symptoms of psoriatic arthritis:results of the IMPACT 2 trial[J].Annals of the Rheumatic Diseases,2005,(08):1150-1157.
共引文献3
-
1王红现.白芍总苷联合复方氟米松软膏治疗寻常性银屑病疗效观察[J].河南医学研究,2016,25(9):1680-1681.
-
2齐婧,解方,刘卉莹,宋翠豪,李承新.英夫利西单抗治疗中重度银屑病的疗效及安全性研究[J].中国药物应用与监测,2019,16(6):325-327. 被引量:3
-
3张翰林,舒畅,晋红中.生物制剂治疗银屑病的研究进展[J].中国科学:生命科学,2021,51(8):1050-1059. 被引量:12
同被引文献20
-
1Schrn MP, Boehncke WH. Psoriasis[J]. N Engl J Med, 2005, 352 (18): 1899-1912. DOI: 10.1056/NEJMra041320.
-
2Luber AJ, Tsui CL, Heinecke GM, et al. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis [J]. J Am Acad Dermatol, 2014, 70 (3): 525-532. DOI: 10.1016/j.jaad. 2013.10.059.
-
3Dotan I, Ran Y, Yanai H, et al. Patient factors that increase infli- ximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study [J]. Inflamm Bowel Dis, 2014, 20 (12): 2247-2259. DOI: 10.1097/MIB. 0000000000000212.
-
4Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double- blind, placebo-controlled trial [J]. J Am Acad Dermatol, 2004, 51 (4): 534-542. DOI: 10.1016/j.jaad.2004.02.021.
-
5Wetter DA, Davis MD. Lupus-like syndrome attributable to anti- tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic [ J ]. Mayo Clin Proc, 2009, 84 ( 11 ): 979-984. DOI: 10.4065/84.11.979.
-
6Zhu Chenyu, Sun Qiuning, Shu Chang, et al. Infliximab for the treatment of severe psoriasis in 17 cases: a clinical observational study[J]. Chin J Dermatol, 2016, 49(4): 294-295. DOI: 10.3760/ ema.j .issn.0412-4030.2016.04.021.
-
7丁晓岚,王婷琳,沈佚葳,王晓艳,周城,田珊,刘盈,彭光辉,周俊娥,薛树旗,王仁利,唐英,孟雪梅,裴广德,白云花,刘青,李航,张建中.中国六省市银屑病流行病学调查[J].中国皮肤性病学杂志,2010,24(7):598-601. 被引量:347
-
8刘伦飞,郑敏.英夫利西单抗在银屑病中的应用进展[J].中华皮肤科杂志,2013,46(3):216-219. 被引量:6
-
9余晓玲,晋红中.英夫利西单抗治疗关节病性银屑病进展[J].中华皮肤科杂志,2014,47(3):223-225. 被引量:3
-
10王聪敏,李海涛,余明莲,赵志力,徐晓敏,袁越.心理护理对银屑病患者心理状态的影响[J].实用皮肤病学杂志,2014,7(2):138-139. 被引量:20
引证文献5
-
1李峰,晋红中,何志新,李红春,乔菊,苏飞.英夫利西单抗治疗17例中重度寻常性银屑病[J].中华皮肤科杂志,2016,49(6):437-438. 被引量:4
-
2郑宝庆,王晓华.阿达木单抗联合甲氨蝶呤治疗银屑病患者3例临床观察[J].皮肤性病诊疗学杂志,2018,25(2):69-73. 被引量:1
-
3刘勇华.英夫利西单抗治疗中重度斑块状银屑病患者生活质量的研究[J].实用皮肤病学杂志,2018,11(5):282-285. 被引量:9
-
4齐婧,解方,刘卉莹,宋翠豪,李承新.英夫利西单抗治疗中重度银屑病的疗效及安全性研究[J].中国药物应用与监测,2019,16(6):325-327. 被引量:3
-
5高蓉,张兰,李政霄.生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展[J].中华皮肤科杂志,2022,55(1):72-75. 被引量:15
二级引证文献29
-
1陈金花.司库奇尤单抗治疗中重度斑块状银屑病患者的效果及临床护理分析[J].黑龙江中医药,2023,52(1):162-164.
-
2陈慧姮,梁晓冬,邓婕,薛如君,梁景耀,叶瑞贤,张锡宝.阿维A与甲氨蝶呤联合治疗难治性中重度银屑病疗效观察[J].中国皮肤性病学杂志,2018,32(5):610-614. 被引量:13
-
3齐婧,解方,刘卉莹,宋翠豪,李承新.英夫利西单抗治疗中重度银屑病的疗效及安全性研究[J].中国药物应用与监测,2019,16(6):325-327. 被引量:3
-
4彭淑仪,莫雪兰,许秀英.银屑病综合治疗及护理效果评价[J].中外医学研究,2020,18(3):87-88. 被引量:5
-
5程庆,王晓华,杨斌.寻常型银屑病患者体内半乳糖凝集素家族蛋白表达研究[J].皮肤性病诊疗学杂志,2020,27(3):141-146. 被引量:1
-
6徐维春.308 nm准分子激光联合0.1%他克莫司软膏治疗斑块状银屑病临床疗效观察[J].齐齐哈尔医学院学报,2020,41(15):1865-1866. 被引量:2
-
7刘薇薇.不同波谱紫外线照射治疗寻常型银屑病的疗效对比[J].中国医药指南,2020,18(27):107-108.
-
8宋青蔓.联合应用辛伐他汀在局部药物治疗寻常型银屑病中的效果[J].实用中西医结合临床,2020,20(15):96-97. 被引量:3
-
9张翰林,舒畅,晋红中.生物制剂治疗银屑病的研究进展[J].中国科学:生命科学,2021,51(8):1050-1059. 被引量:12
-
10秦月宁.英夫利西单抗治疗中重度银屑病的效果与不良反应观察[J].中国社区医师,2022,38(1):30-32. 被引量:2
-
1陆家睛,高芸璐,丁杨峰,张怡.英夫利西单抗治疗寻常性银屑病2例[J].临床皮肤科杂志,2017,46(4):285-288.
-
2李峰,晋红中,何志新,李红春,乔菊,苏飞.英夫利西单抗治疗17例中重度寻常性银屑病[J].中华皮肤科杂志,2016,49(6):437-438. 被引量:4
-
3张堂德,李琳琳,罗妙璇.英夫利西单抗治疗寻常性银屑病七例[J].中华皮肤科杂志,2015,48(6):438-439. 被引量:3
-
4路涛,邹金渡,章淑平,陈晶,黄雄.英夫利西单抗治疗重度斑块状银屑病一例[J].中华皮肤科杂志,2016,49(4).
-
5孙婧,周敏,姚煦.英夫利西单抗治疗寻常性银屑病一例[J].中华皮肤科杂志,2016,49(4).
-
6葛帮友,金汝钧,孙东玲.95例早期梅毒合并其他STD临床分析[J].中国麻风皮肤病杂志,2007,23(11):1034-1034.
-
7方玲玲.带状疱疹后遗神经痛的预防及治疗进展[J].中国医学文摘(皮肤科学),2010,27(2):81-83. 被引量:12
-
8尹光文,于建斌,何秋波,傅世珍.重症药疹72例临床分析[J].中国麻风皮肤病杂志,2001,17(2):113-114.
-
9窦颖,谢延军.336例老年性传播疾病临床分析[J].中国麻风皮肤病杂志,2004,20(6):590-591. 被引量:9
-
10孙彩虹,顾恒.甲银屑病与英夫利西单抗[J].中华皮肤科杂志,2013,46(3):219-221.